

Amendment

In the Claims

Claims 1-3 (canceled)

4. (currently amended) A method for inhibiting symptoms associated with angiogenesis in the treatment of skin disorders selected from the group consisting of skin disorders associated with lymphangiogenesis, Sturge-Weber syndrome, verruca vulgaris, tuberous sclerosis, venous ulcers, molluscum contagious, seborrheic keratosis, and actinic keratosis comprising administering to the individual in need of treatment thereof an angiogenesis inhibitor wherein the angiogenesis inhibitor is selected from the group consisting of collagenase inhibitors, angiogenic fumagillin derivatives, 2,5-diaryltetrahydrofurans, aminophenylphosphonic acid compounds, 3-substituted oxindole derivatives, thalidomides, penicillamine and IL12 in an amount effective to inhibit angiogenesis.

5. (original) The method of claim 4 wherein the angiogenesis inhibitor is applied topically.

6. (previously presented) The method of claim 5 wherein the angiogenesis inhibitor is TNF-470.

Claims 7-9 (canceled)

10. (currently amended) A method to treat the symptoms associated with elevated basic fibroblast growth factor in a disorder selected from the group consisting of angiosarcoma, hemangioendothelioma, basal cell carcinoma, squamous cell carcinoma, malignant melanoma,

Kaposi's sarcoma, psoriasis; and recessive dystrophic epidermolysis bullosa, comprising administering to the individual in need of treatment an effective amount of a pharmaceutical composition comprising a curcuminoid in combination with a pharmaceutically acceptable carrier to inhibit angiogenesis, wherein the carrier is an ointment for topical administration containing between one-half percent (0.5%) and five percent (5%) of the curcuminoid or a polymer formulation for implantation.

11. (previously presented) The method of claim 10 wherein the curcuminoid is curcumin.

12. (previously presented) The method of claim 10 wherein the curcuminoid is demethoxycurcumin.

Claims 13-16 (canceled)

17. (currently amended) A method for inhibiting skin disorders selected from the group consisting of skin disorders associated with lymphangiogenesis, Sturge-Weber syndrome, verruca vulgaris, tuberous sclerosis, venous ulcers, rosacea, eczema, molluscum contagiosum, seborrheic keratosis, and actinic keratosis comprising administering to the individual in need of treatment thereof an angiogenesis inhibitor in an amount effective to inhibit angiogenesis, wherein the angiogenesis inhibitor is selected from the group consisting of tetracyclines inhibiting collagenase, and a sulfated polysaccharide which inhibits angiogenesis.

U.S.S.N. 09/765,491

Filed: January 18, 2001

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 41.50(b)(1)

18. (previously presented) The method of claim 10 wherein the disorder is malignant melanoma.
19. (previously presented) The method of claim 10 wherein the disorder is recessive dystrophic epidermolysis bullosa.